| abstract |
Reagents which regulate human lysostaphin-like protease activity and reagents which bind to human lysostaphin-like protease gene products can be used to regulate extracellular matrix degradation. Such regulation is particularly useful for treating metastasis of malignant cells, tumor angiogenesis, inflammation, cardiovascular disease, including hypertension, aneurysmal dilatation, and atherosclerosis, neurodegenerative diseases, and pathogenic infections. |